News

Sleep disorders are common in primary biliary cholangitis (PBC) and signal that the disease is more severe.

A new analysis compared second-line PBC therapies and found seladelpar 10 mg had a favorable balance of efficacy, itch relief and safety.

After a liver transplant, a higher chance of dying seems connected more to poor kidney function and older age than to liver failure.

Among patients who did start first-line treatment, almost 60% stopped taking it and never started a second-line therapy.

A randomized trial found that reducing UDCA to 10 mg/kg/day may maintain disease control in PBC, while 5 mg/kg/day increased relapse risk.

Higher CCL2 activity in high-risk PBC may point to a connection between gut bacteria-related substances and immune changes in the liver.

Cholestatic pruritus, the itch in PBC, resists older therapies, but newer treatments target its underlying causes.

A citrus-derived supplement for PBC modestly lowered GGT, supporting further research into its use alongside existing treatment.

Obeticholic acid was found safe and effective over six years in people with PBC, according to the final POISE extension trial results.

Researchers identified consistent patterns in the gut microbiome of people with PBC, hinting it may play a role in the disease.